Publicaciones (48) Publicaciones en las que ha participado algún/a investigador/a

2024

  1. Anti-retinal Antibodies in Sarcoidosis

    Ocular Immunology and Inflammation, Vol. 32, Núm. 2, pp. 141-147

  2. Aprendizaje-Servicio en el entorno rural de León

    Innovación docente en la Universidad de León (Servicio de Publicaciones), pp. 165-172

  3. Correction to: Protective Effect of Protocatechuic Acid on TNBS-Induced Colitis in Mice Is Associated with Modulation of the SphK/S1P Signaling Pathway (Nutrients, (2017), 9, 3, (288), 10.3390/nu9030288)

    Nutrients

  4. Correction to: Role of Toll-like receptor 2 and 4 signaling pathways on the inflammatory response to resistance training in elderly subjects (AGE, (2014), 36, 6, (9734), 10.1007/s11357-014-9734-0)

    GeroScience

  5. Corrigendum: Molecular characterization of autophagic and apoptotic signaling induced by sorafenib in liver cancer cells (Journal of Cellular Physiology, 10.1002/jcp.26855)

    Journal of Cellular Physiology

  6. Editorial: Molecular mechanisms underlying exercise-alleviated sarcopenic obesity

    Frontiers in Endocrinology

  7. Efficacy and safety of regorafenib as a first-line agent alone or in combination with an immune checkpoint inhibitor for advanced hepatocellular carcinoma: a retrospective cohort study

    Journal of Gastrointestinal Oncology, Vol. 15, Núm. 3, pp. 1072-1081

  8. Impact of BMI and Cardiorespiratory Fitness on Oxidative Stress in Plasma and Circulating Exosomes Following Acute Exercise

    Biology, Vol. 13, Núm. 8

  9. Prevalence of sarcopenic obesity according to different diagnostic methods and cut-off points in candidates for bariatric surgery

    Clinical Nutrition, Vol. 43, Núm. 5, pp. 1087-1093

  10. Retraction: “Inhibition of the SphK1/S1P Signaling Pathway by Melatonin in Mice with Liver Fibrosis and Human Hepatic Stellate Cells,” (BioFactors, (2016), 43, 2, (272–82), 10.1002/biof.1342)

    BioFactors

  11. Retraction:“Inhibition of the SphK1/S1P Signaling Pathway by Melatonin in Mice with Liver Fibrosis and Human Hepatic Stellate Cells,” (BioFactors, (2016), 43, 2, (272–82), 10.1002/biof.1342)

    BioFactors

  12. Risk versus Benefit of Tyrosine Kinase Inhibitors for Hepatocellular Carcinoma: A Systematic Review and Meta-Analysis of Randomized Controlled Trials

    Clinical Pharmacology and Therapeutics, Vol. 116, Núm. 2, pp. 328-345

  13. Strategies to enhance the response of liver cancer to pharmacological treatments

    American journal of physiology. Cell physiology, Vol. 327, Núm. 1, pp. C11-C33

2023

  1. Correction to: Stabilization of Hypoxia-Inducible Factors and BNIP3 Promoter Methylation Contribute to Acquired Sorafenib Resistance in Human Hepatocarcinoma Cells (Cancers, (2019), 11, 12, (1984), 10.3390/cancers11121984)

    Cancers

  2. Hepatocellular carcinoma cells loss lenvatinib efficacy in vitro through autophagy and hypoxia response-derived neuropilin-1 degradation

    Acta Pharmacologica Sinica, Vol. 44, Núm. 5, pp. 1066-1082

  3. Impact of Aberrant β-Catenin Pathway on Cholangiocarcinoma Heterogeneity

    Cells, Vol. 12, Núm. 8

  4. Influence of 12-Week Concurrent Training on Exosome Cargo and Its Relationship with Cardiometabolic Health Parameters in Men with Obesity

    Nutrients, Vol. 15, Núm. 13

  5. Neuropilins as potential biomarkers in hepatocel-lular carcinoma: a systematic review of basic and clinical implications

    Clinical and Molecular Hepatology, Vol. 29, Núm. 2, pp. 293-319

  6. Relationship Between Surface Temperature, Body Composition and Anthropometric Indicators of Obesity and Overweight

    International Journal of Morphology, Vol. 41, Núm. 6, pp. 1824-1832

  7. Therapeutic approaches in intermediate-stage hepatocellular carcinoma (HCC): a novel insight of adjuvant transarterial chemoembolization (TACE)

    Chinese Clinical Oncology